ProQR Therapeutics NV
(NASDAQ : PRQR)

( )
PRQR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
LLYEli Lilly & Co. 1.08%365.631.1%$1192.52m
JNJJohnson & Johnson 0.12%177.220.7%$1097.25m
MRKMerck & Co., Inc. 0.60%107.460.7%$994.87m
PFEPfizer Inc. 0.72%49.200.9%$981.12m
ABBVAbbVie, Inc. 0.14%159.611.9%$906.78m
BMYBristol-Myers Squibb Co. 0.16%79.271.1%$751.13m
AZNAstraZeneca Plc 0.08%66.171.0%$360.17m
IDXXIDEXX Laboratories, Inc. -1.24%411.363.9%$222.64m
GSKGSK Plc 0.89%33.990.3%$202.02m
HZNPHorizon Therapeutics Plc 0.97%78.285.4%$201.37m
NVSNovartis AG 0.57%87.790.2%$190.04m
CTLTCatalent, Inc. -1.83%41.411.9%$163.88m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%212.728.0%$159.13m
NVONovo Nordisk A/S 0.86%118.840.1%$155.62m
SGENSeagen Inc. -0.42%123.445.7%$122.67m

Company Profile

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.